Moderna shares surge as Merck-partnered melanoma vaccine cuts recurrence in large trial
- Posted on August 19, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Moderna shares surge as Merck-partnered melanoma vaccine cuts recurrence in large trial
By Julie Steenhuysen and Michael Erman CHICAGO, Aug 19 (Reuters) - Moderna's personalized mRNA cancer therapy, developed with Merck, reduced the risk of recurrence and spread of skin cancer in a late-stage trial when combined with immunotherapy drug Keytruda, sending Moderna's shares up around 150% to multi-year highs. Thousands of patients who have undergone surgery for high-risk melanoma could